Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sukwon Hong

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
ACS Infectious Diseases|September 1, 2020
Helicity Modulation Improves the Selectivity of Antimicrobial PeptoidsHo Yeon Nam, Jieun Choi, S Dinesh Kumar, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2007
An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonistsLisa M Eubanks, Mark S Hixon, Wei Jin, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
CerS2 is a druggable target in triple-negative breast cancerHissah Alatawi, Haritha H Nair, Lingbao Ai, et al.
Molecular Cancer Therapeutics|April 21, 2026
CerS2 is a druggable target in triple-negative breast cancerHissah Alatawi, Haritha H Nair, Lingbao Ai, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
ACS Infectious Diseases|September 1, 2020
Helicity Modulation Improves the Selectivity of Antimicrobial PeptoidsHo Yeon Nam, Jieun Choi, S Dinesh Kumar, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2007
An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonistsLisa M Eubanks, Mark S Hixon, Wei Jin, et al.
Biorxiv : the Preprint Server for Biology|September 2, 2025
CerS2 is a druggable target in triple-negative breast cancerHissah Alatawi, Haritha H Nair, Lingbao Ai, et al.
Molecular Cancer Therapeutics|April 21, 2026
CerS2 is a druggable target in triple-negative breast cancerHissah Alatawi, Haritha H Nair, Lingbao Ai, et al.
Pageof 4